Minister of Health Issues Decision to Regulate Biological Therapies

- Its prescription, dispensing, and follow-up are conducted in accordance with scientific controls.

- It enhances the governance of the therapeutic system, patient safety, and expenditure efficiency.

The Minister of Health, Dr. Ahmed Abdulwahab Al-Awadi, issued a ministerial decision to regulate the prescription, dispensing, and follow-up of biological treatments at the Ministry of Health, a move that strengthens the governance of the pharmaceutical system, ensures patient safety, improves expenditure efficiency, and prepares for future treatments.

The Ministry of Health stated in a press release that the decision establishes the first comprehensive regulatory framework for biological treatments within the ministry, regulating all stages of biological therapy, from its prescription and dispensing to the monitoring of its clinical and economic outcomes.

The ministry clarified that the decision sets clear guidelines for patient selection, approval of treatment protocols, and ensuring that the right treatment reaches the right patient at the right time.

It added that the decision regulates the use of genetic and cellular therapies, CAR-T treatments, and advanced therapies, in accordance with the highest scientific and operational standards.

The ministry noted that the decision relies on the scientific use of biosimilar biological treatments, following approved protocols that ensure quality and enhance expenditure efficiency.

The ministry emphasized that patient safety is the top priority of the decision, achieved by strengthening pharmacovigilance, tracking biological treatments, reporting side effects, and establishing records to monitor outcomes and safety indicators.